Opposite Roles of NMDA Receptors in Relapsing and Primary Progressive Multiple Sclerosis

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Rossi, Silvia ^a,b   Studer, Valeria ^a,b   Moscatelli, Alessandro ^f   Motta, Caterina ^a,b   Coghe, Giancarlo ^c   Fenu, Giuseppe ^c   Caillier, Stacy ^d   Buttari, Fabio ^a,b   Mori, Francesco ^a,b   Barbieri, Francesca ^a,b   Castelli, Maura ^a,b   de Chiara, Valentina ^a,b   Monteleone, Fabrizia ^a,b   Mancino, Raffaele ^e   Bernardi, Giorgio ^a,b   Baranzini, Sergio E ^d   Marrosu, Maria G ^c   Oksenberg, Jorge R ^d   Centonze, Diego ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f BIELEFELD UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B;

ADULT; ALLELE; ARTICLE; COGNITION; CONTROLLED STUDY; DISABILITY; DISEASE ACTIVITY; DISEASE SEVERITY; EXCITOTOXICITY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NERVE CELL PLASTICITY; NERVE EXCITABILITY; NERVE FIBER DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROTEIN FUNCTION; RELAPSE; RETINAL NERVE FIBER LAYER THICKNESS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VISUAL ACUITY;

ADULT; CEREBRAL CORTEX; COGNITION; DISEASE PROGRESSION; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; LOGISTIC MODELS; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NERVE TISSUE PROTEINS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, N-METHYL-D-ASPARTATE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84879513072     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067357     Document Type: Article

References (111)

1. Centonze D, Rossi S, Tortiglione A, Picconi B, Prosperetti C, et al. (2007) Synaptic plasticity during recovery from permanent occlusion of the middle cerebral artery. Neurobiol Dis 27: 44-53.
2. Li R, Huang FS, Abbas AK, Wigström H, (2007) Role of NMDA receptor subtypes in different forms of NMDA-dependent synaptic plasticity. BMC Neurosci 8: 55.
3. Yaka R, Biegon A, Grigoriadis N, Simeonidou C, Grigoriadis S, et al. (2007) D-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury. FASEB J 21: 2033-2041.
4. Molina-Luna K, Pekanovic A, Röhrich S, Hertler B, Schubring-Giese M, et al. (2009) Dopamine in motor cortex is necessary for skill learning and synaptic plasticity. PLoS One 4: e7082.
5. Di Lazzaro V, Profice P, Pilato F, Capone F, Ranieri F, et al. (2010) Motor cortex plasticity predicts recovery in acute stroke. Cereb Cortex 20: 1523-1528.
6. Olney JW, (1969) Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 164: 719-721.
7. Albin RL, Greenamyre JT, (1992) Alternative excitotoxic hypotheses. Neurology 42: 733-738.
8. Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, et al. (2007) NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 27: 2846-2857.
9. Forder JP, Tymianski M, (2009) Postsynaptic mechanisms of excitotoxicity: Involvement of postsynaptic density proteins, radicals, and oxidant molecules. Neuroscience 158: 293-300.
10. Matute C, Alberdi E, Domercq M, Pérez-Cerdá F, Pérez-Samartín A, et al. (2001) The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci 24: 224-230.
11. Matute C, (2011) Glutamate and ATP signalling in white matter pathology. J Anat 219: 53-64.
12. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI, (1994) A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 117: 759-765.
13. Miller DH, Leary SM, (2007) Primary-progressive multiple sclerosis. Lancet Neurol 6: 903-912.
14. Compston A, Coles A, (2008) Multiple sclerosis. Lancet 372: 1502-1517.
15. Erreger K, Geballe MT, Kristensen A, Chen PE, Hansen KB, et al. (2007) Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors. Mol Pharmacol 72: 907-920.
16. Gielen M, Siegler Retchless B, Mony L, Johnson JW, Paoletti P, (2009) Mechanism of differential control of NMDA receptor activity by NR2 subunits. Nature 459: 703-707.
17. Mori F, Ribolsi M, Kusayanagi H, Siracusano A, Mantovani V, et al. (2011) Genetic variants of the NMDA receptor influence cortical excitability and plasticity in humans. J Neurophysiol 106: 1637-1643.
18. Firth D, (1993) Bias reduction of maximum likelihood estimates. Biometrika 80: 27-38.
19. Ziemann U, Lönnecker S, Steinhoff BJ, Paulus W, (1996) Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol 40: 367-378.
20. Bosma LV, Kragt JJ, Knol DL, Polman CH, Uitdehaag BM, (2012) Clinical scales in progressive MS: predicting long-term disability. Mult Scler 18: 345-350.
21. Bergamaschi R, Quaglini S, Trojano M, Amato MP, Tavazzi E, et al. (2007) Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. J Neurol Neurosurg Psychiatry 78: 757-759.
22. Bolton C, Paul C, (1997) MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis. J Pharmacol Exp Ther 282: 397-402.
23. Reijerkerk A, Kooij G, van der Pol SM, Leyen T, Lakeman K, et al. (2010) The NR1 subunit of NMDA receptor regulates monocyte transmigration through the brain endothelial cell barrier. J Neurochem 113: 447-453.
24. Neuhaus W, Freidl M, Szkokan P, Berger M, Wirth M, et al. (2011) Effects of NMDA receptor modulators on a blood-brain barrier in vitro model. Brain Res 1394: 49-61.
25. Frohman E, Costello F, Zivadinov R, Stuve O, Conger A, et al. (2006) Optical coherence tomography in multiple sclerosis. Lancet Neurol 5: 853-863.
26. Frohman EM, Fujimoto JG, Frohman TC, Calabresi PA, Cutter G, et al. (2008) Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol 4: 664-675.
27. Barkhof F, Calabresi PA, Miller DH, Reingold SC, (2009) Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 5: 256-266.
28. Burkholder BM, Osborne B, Loguidice MJ, Bisker E, Frohman TC, et al. (2009) Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol 66: 1366-1372.
29. Baier ML, Cutter GR, Rudick RA, Miller D, Cohen JA, et al. (2005) Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology 64: 992-995.
30. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837-842.
31. Mori F, Rossi S, Sancesario G, Codecà C, Mataluni G, et al. (2011) Cognitive and cortical plasticity deficits correlate with altered amyloid-β CSF levels in multiple sclerosis. Neuropsychopharmacology 36: 559-568.
32. Amato MP, Portaccio E, Goretti B, Zipoli V, Battaglini M, et al. (2007) Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol 64: 1157-1161.
33. Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, et al. (2009) Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 66: 1144-1150.
34. Kiy G, Lehmann P, Hahn HK, Eling P, Kastrup A, et al. (2011) Decreased hippocampal volume, indirectly measured, is associated with depressive symptoms and consolidation deficits in multiple sclerosis. Mult Scler 17: 1088-1097.
35. Stover JF, Lowitzsch K, Kempski OS, (1997) Cerebrospinal fluid hypoxanthine, xanthine and uric acid levels may reflect glutamate-mediated excitotoxicity in different neurological diseases. Neurosci Lett 238: 25-28.
36. Killestein J, Kalkers NF, Polman CH, (2005) Glutamate inhibition in MS: the neuroprotective properties of riluzole. J Neurol Sci 233: 113-115.
37. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D, (2005) Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain. 128: 1016-1025.
38. Cianfoni A, Niku S, Imbesi SG, (2007) Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. AJNR Am J Neuroradiol 28: 272-277.
39. Newcombe J, Uddin A, Dove R, Patel B, Turski L, et al. (2008) Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol 18: 52-61.
40. Baranzini SE, Srinivasan R, Khankhanian P, Okuda DT, Nelson SJ, et al. (2010) Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. Brain 133: 2603-2611.
41. Pampliega O, Domercq M, Soria FN, Villoslada P, Rodríguez-Antigüedad A, et al. (2011) Increased expression of cystine/glutamate antiporter in multiple sclerosis. J Neuroinflammation 8: 63.
42. McEachern JC, Shaw CA, (1999) The plasticity-pathology continuum: defining a role for the LTP phenomenon. J Neurosci Res 58: 42-61.
43. Calabresi P, Centonze D, Pisani A, Cupini L, Bernardi G, (2003) Synaptic plasticity in the ischaemic brain. Lancet Neurol 2: 622-629.
44. Que M, Schiene K, Witte OW, Zilles K, (1999) Widespread up-regulation of N-methyl-D-aspartate receptors after focal photothrombotic lesion in rat brain. Neurosci Lett 273: 77-80.
45. Di Filippo M, Tozzi A, Costa C, Belcastro V, Tantucci M, et al. (2008) Plasticity and repair in the post-ischemic brain. Neuropharmacology 55: 353-362.
46. Picconi B, Tortiglione A, Barone I, Centonze D, Gardoni F, et al. (2006) NR2B subunit exerts a critical role in postischemic synaptic plasticity. Stroke 37: 1895-1901.
47. Ding YX, Zhang Y, He B, Yue WH, Zhang D, et al. (2010) A possible association of responsiveness to adrenocorticotropic hormone with specific GRIN1 haplotypes in infantile spasms. Dev Med Child Neurol 52: 1028-1032.
48. Endele S, Rosenberger G, Geider K, Popp B, Tamer C, et al. (2010) Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat Genet 42: 1021-1026.
49. Chen C, Li X, Wang T, Wang HH, Fu Y, et al. (2010) Association between NMDA receptor subunit 2b gene polymorphism and Alzheimer's disease in Chinese Han population in Shanghai. Neurosci Bull 26: 395-400.
50. Wu SL, Wang WF, Shyu HY, Ho YJ, Shieh JC, et al. (2010) Association analysis of GRIN1 and GRIN2B polymorphisms and Parkinson's disease in a hospital-based case-control study. Neurosci Lett 478: 61-65.
51. Galehdari H, Pooryasin A, Foroughmand A, Daneshmand S, Saadat M, (2009) Association between the G1001C polymorphism in the GRIN1 gene promoter and schizophrenia in the Iranian population. J Mol Neurosci 38: 178-181.
52. Arnold PD, Macmaster FP, Richter MA, Hanna GL, Sicard T, et al. (1995) Glutamate receptor gene (GRIN2B) associated with reduced anterior cingulate glutamatergic concentration in pediatric obsessive-compulsive disorder.
53. Dorval KM, Wigg KG, Crosbie J, Tannock R, Kennedy JL, et al. (2007) Association of the glutamate receptor subunit gene GRIN2B with attention-deficit/hyperactivity disorder. Genes Brain Behav 6: 444-452.
54. Mundo E, Tharmalingham S, Neves-Pereira M, Dalton EJ, Macciardi F, et al. (2003) Evidence that the N-methyl-D-aspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder. Mol Psychiatry 8: 241-245.
55. Collingridge GL, Bliss TV, (1995) Memories of NMDA receptors and LTP. Trends Neurosci 18: 54-56.
56. Nicoll RA, Malenka RC, (1999) Expression mechanisms underlying NMDA receptor-dependent long-term potentiation. Ann N Y Acad Sci 868: 515-525.
57. Milnerwood AJ, Raymond LA, (2010) Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci 33: 513-523.
58. Pivovarova NB, Andrews SB, (2010) Calcium-dependent mitochondrial function and dysfunction in neurons. FEBS J 277: 3622-3636.
59. Calabresi P, Centonze D, Pisani A, Sancesario G, Gubellini P, et al. (1998) Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease. Ann Neurol 43: 586-597.
60. Errico F, Nisticò R, Palma G, Federici M, Affuso A, et al. (2008) Increased levels of d-aspartate in the hippocampus enhance LTP but do not facilitate cognitive flexibility. Mol Cell Neurosci 37: 236-246.
61. Errico F, Nisticò R, Napolitano F, Mazzola C, Astone D, et al. (2011) Increased D-aspartate brain content rescues hippocampal age-related synaptic plasticity deterioration of mice. Neurobiol Aging 32: 2229-2243.
62. Errico F, Nisticò R, Napolitano F, Oliva AB, Romano R, et al. (2011) Persistent increase of D-aspartate in D-aspartate oxidase mutant mice induces a precocious hippocampal age-dependent synaptic plasticity and spatial memory decay. Neurobiol Aging 32: 2061-2074.
63. Villoslada P, Arrondo G, Sepulcre J, Alegre M, Artieda J, (2009) Memantine induces reversible neurologic impairment in patients with MS. Neurology 72: 1630-1633.
64. Rosenstock TR, Bertoncini CR, Teles AV, Hirata H, Fernandes MJ, et al. (2010) Glutamate-induced alterations in Ca2+ signaling are modulated by mitochondrial Ca2+ handling capacity in brain slices of R6/1 transgenic mice. Eur J Neurosci 32: 60-70.
65. Stanika RI, Winters CA, Pivovarova NB, Andrews SB, (2010) Differential NMDA receptor-dependent calcium loading and mitochondrial dysfunction in CA1 vs. CA3 hippocampal neurons. Neurobiol Dis 37: 403-411.
66. Kambe Y, Nakamichi N, Takarada T, Fukumori R, Nakazato R, et al. (2011) A possible pivotal role of mitochondrial free calcium in neurotoxicity mediated by N-methyl-d-aspartate receptors in cultured rat hippocampal neurons. Neurochem Int 59: 10-20.
67. Kalman B, Laitinen K, Komoly S, (2007) The involvement of mitochondria in the pathogenesis of multiple sclerosis. J Neuroimmunol 188: 1-12.
68. Witte ME, Geurts JJ, de Vries HE, van der Valk P, van Horssen J, (2010) Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration? Mitochondrion 10: 411-418.
69. Campbell GR, Ziabreva I, Reeve AK, Krishnan KJ, Reynolds R, et al. (2011) Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol 69: 481-492.
70. Peurala SH, Müller-Dahlhaus JF, Arai N, Ziemann U, (2008) Interference of short-interval intracortical inhibition (SICI) and short-interval intracortical facilitation (SICF). Clin Neurophysiol 119: 2291-2297.
71. Ziemann U, Chen R, Cohen LG, Hallett M, (1998) Dextromethorphan decreases the excitability of the human motor cortex. Neurology 51: 1320-1324.
72. Schwenkreis P, Witscher K, Janssen F, Addo A, Dertwinkel R, et al. (1999) Influence of the N-methyl-D-aspartate antagonist memantine on human motor cortex excitability. Neurosci Lett 270: 137-140.
73. Schwenkreis P, Liepert J, Witscher K, Fischer W, Weiller C, et al. (2000) Riluzole suppresses motor cortex facilitation in correlation to its plasma level. A study using transcranial magnetic stimulation. Exp Brain Res 135: 293-299.
74. Porter RH, Greene JG, Higgins DS Jr, Greenamyre JT, (1994) Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion. J Neurosci 14: 7192-7199.
75. Rodriguez MC, Obeso JA, Olanow CW, (1998) Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 44: S175-S188.
76. Greenamyre JT, (2001) Glutamatergic influences on the basal ganglia. Clin Neuropharmacol 24: 65-70.
77. Georgi A, Jamra RA, Klein K, Villela AW, Schumacher J, et al. (2007) Possible association between genetic variants at the GRIN1 gene and schizophrenia with lifetime history of depressive symptoms in a German sample. Psychiatr Genet 17: 308-310.
78. Qin S, Zhao X, Pan Y, Liu J, Feng G, et al. (2005) An association study of the N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray. Eur J Hum Genet 13: 807-814.
79. Halene TB, Ehrlichman RS, Liang Y, Christian EP, Jonak GJ, et al. (2009) Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia. Genes Brain Behav 8: 661-675.
80. Bai G, Kusiak JW, (1995) Functional analysis of the proximal 5'-flanking region of the N-methyl-D-aspartate receptor subunit gene, NMDAR1. J Biol Chem 270: 7737-7744.
81. Bennett MR, (2000) The concept of long term potentiation of transmission at synapses. Prog Neurobiol 60: 109-137.
82. Cooke SF, Bliss TV, (2005) Long-term potentiation and cognitive drug discovery. Curr Opin Investig Drugs 6: 25-34.
83. Cooke SF, Bliss TV, (2006) Plasticity in the human central nervous system. Brain 129: 1659-1673.
84. Miglio G, Varsaldi F, Lombardi G, (2005) Human T lymphocytes express N-methyl-D-aspartate receptors functionally active in controlling T cell activation. Biochem Biophys Res Commun 338: 1875-1883.
85. Schipke CG, Ohlemeyer C, Matyash M, Nolte C, Kettenmann H, et al. (2001) Astrocytes of the mouse neocortex express functional N-methyl-D-aspartate receptors. FASEB J 15: 1270-1272.
86. Grasselli G, Rossi S, Musella A, Gentile A, Loizzo S, et al. (2013) Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis. Br J Pharmacol 168: 502-517.
87. Káradóttir R, Cavelier P, Bergersen LH, Attwell D, (2005) NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 438: 1162-1166.
88. Salter MG, Fern R, (2005) NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 438: 1167-1171.
89. Micu I, Jiang Q, Coderre E, Ridsdale A, Zhang L, et al. (2006) NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature 439: 988-992.
90. Gordon-Lipkin E, Chodkowski B, Reich DS, Smith SA, Pulicken M, et al. (2007) Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 69: 1603-1609.
91. Grazioli E, Zivadinov R, Weinstock-Guttman B, Lincoff N, Baier M, et al. (2008) Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci 268: 12-17.
92. Costello F, Hodge W, Pan YI, Freedman M, DeMeulemeester C, (2009) Differences in retinal nerve fiber layer atrophy between multiple sclerosis subtypes. J Neurol Sci 281: 74-79.
93. Sucher NJ, Lipton SA, Dreyer EB, (1997) Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res 37: 3483-3493.
94. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58: 840-846.
95. Kurtzke JF, (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452.
96. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, et al. (2005) Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 64: 1144-1151.
97. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, et al. (1999) Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122: 871-882.
98. Rao SM, Cognitive Function Study Group of the National Multiple Sclerosis Society (1990) A manual for the Brief Repeatable Battery of Neuropsychological Tests in multiple sclerosis. New York: National Multiple Sclerosis Society.
99. Amato MP, Bartolozzi ML, Zipoli V, Portaccio E, Mortilla M, et al. (2004) Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology 63: 89-93.
100. Amato MP, Portaccio E, Goretti B, Zipoli V, Ricchiuti L, et al. (2006) The Rao's Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. Mult Scler 12: 787-793.
101. Barbarotto R, Laiacona M, Frosio R, Vecchio M, Farinato A, et al. (1998) A normative study on visual reaction times and two Stroop colour-word tests. Ital J Neurol Sci 19: 161-170.
102. Camp SJ, Stevenson VL, Thompson AJ, Miller DH, Borras C, et al. (1999) Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Brain 122: 1341-1348.
103. Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, et al. (2009) Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Mult Scler 15: 779-788.
104. Patti F, (2009) Cognitive impairment in multiple sclerosis. Mult Scler 15: 2-8.
105. Rossi S, Mancino R, Bergami A, Mori F, Castelli M, et al. (2011) Potential role of IL-13 in neuroprotection and cortical excitability regulation in multiple sclerosis. Mult Scler 17: 1301-1312.
106. Kujirai T, Caramia MD, Rothwell JC, Day BL, Thompson PD, et al. (1993) Corticocortical inhibition in human motor cortex. J Physiol 471: 501-519.
107. Jurinke C, van den Boom D, Cantor CR, Köster H, (2002) Automated genotyping using the DNA MassArray technology. Methods Mol Biol 187: 179-192.
108. Holm S, (1979) A simple sequentially rejective multiple test procedure. Scand J Statistics 6: 65-70.
109. Ellis NA, Huo D, Yildiz O, Worrillow LJ, Banerjee M, et al. (2008) MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 112: 741-749.
110. Agresti A (2002) Categorical Data Analysis. New York: Wiley.
111. Sombekke MH, Arteta D, van de Wiel MA, Crusius JB, Tejedor D, et al. (2010) Analysis of multiple candidate genes in association with phenotypes of multiple sclerosis. Mult Scler 16: 652-659.